Zoetis Inc.
boothcheck covers Zoetis Inc. (ZTS) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed August 7, 2026.
• Two thirds of this company is pets and one third is farm animals, and in the June 2026 quarter the two moved in opposite directions: United States companion animal sales fell 11% while United States livestock sales rose 23%, and the international business grew 6% on an organic operational basis [Source: Q2 2026 earnings release, August 6, 2026]. • The risk is no longer hypothetical, because management has already conceded it: on August 6, 2026 Zoetis revised its full-year plan to organic oper
Is ZTS overvalued? See what's priced in →
1,566 institutional managers reported holding ZTS in 13F filings for the quarter ended 2026-03-31. 124 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 16.1M shares were sold short as of the 2026-06-15 count, about 4% of shares outstanding (2.4 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
ZTS has cut its share count 11.1% over the past five years, spending $8.82B on repurchases. It pays a dividend, and has paid one every year in our records (14 and counting), raised 13 years straight; the current rate is $2.03 a share annually. Cash returned over the past three years: $2.24B in dividends and $6.22B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at ZTS over the trailing three years. Absence is a fact about the company, not a signal. 23 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
ZTS's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-09 | +4.8% | -6.5% |
| 2023-11-03 | +7.1% | +20.1% |
| 2024-02-14 | -6.4% | -17.5% |
| 2024-05-03 | +5.4% | +4.7% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
ZTS's latest 8-K filings: 2026-08-06 (items 5.02, 9.01); 2026-08-06 (items 2.02, 9.01); 2026-05-22 (items 5.02, 5.07); 2026-05-20 (items 7.01, 9.01); 2026-05-07 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: August 7, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.